BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by HealthInvest Partners AB

HealthInvest Partners AB boosted its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 92.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 103,032 shares of the company’s stock after purchasing an additional 49,600 shares during the period. BridgeBio Pharma makes up approximately 1.3% of HealthInvest Partners AB’s holdings, making the stock its 23rd biggest position. HealthInvest Partners AB owned about 0.05% of BridgeBio Pharma worth $2,815,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. CWM LLC lifted its position in shares of BridgeBio Pharma by 132.9% during the 3rd quarter. CWM LLC now owns 3,442 shares of the company’s stock valued at $88,000 after acquiring an additional 1,964 shares during the last quarter. Advisors Asset Management Inc. raised its position in shares of BridgeBio Pharma by 56.1% during the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock worth $117,000 after purchasing an additional 1,645 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of BridgeBio Pharma by 17.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock valued at $135,000 after purchasing an additional 801 shares during the last quarter. Avanza Fonder AB acquired a new position in shares of BridgeBio Pharma in the 4th quarter valued at $181,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in BridgeBio Pharma by 21.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,801 shares of the company’s stock worth $170,000 after purchasing an additional 1,214 shares in the last quarter. 99.85% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on BBIO shares. Citigroup upped their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Friday. Scotiabank upped their price target on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Friday. Bank of America lifted their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Cantor Fitzgerald reissued an “overweight” rating and set a $95.00 target price on shares of BridgeBio Pharma in a research note on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $49.00 target price on shares of BridgeBio Pharma in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $51.67.

BridgeBio Pharma Price Performance

Shares of NASDAQ BBIO opened at $36.85 on Monday. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $39.47. The business’s 50-day moving average price is $31.90 and its two-hundred day moving average price is $27.98. The company has a market capitalization of $6.96 billion, a P/E ratio of -12.93 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million. On average, equities analysts anticipate that BridgeBio Pharma, Inc. will post -3.66 EPS for the current year.

Insiders Place Their Bets

In other BridgeBio Pharma news, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $34.90, for a total transaction of $106,989,998.40. Following the completion of the sale, the insider now directly owns 22,055,375 shares in the company, valued at $769,732,587.50. This represents a 12.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Neil Kumar sold 31,543 shares of BridgeBio Pharma stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $36.14, for a total value of $1,139,964.02. Following the completion of the transaction, the chief executive officer now owns 211,718 shares in the company, valued at $7,651,488.52. The trade was a 12.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,496,239 shares of company stock valued at $122,612,036 over the last ninety days. Corporate insiders own 24.66% of the company’s stock.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.